Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Modeling Epidermal Growth Factor Inhibitor-Mediated Enhancement of Photodynamic Therapy Efficacy Using 3D Mesothelioma Cell Culture.

Cramer G, Shin M, Hagan S, Katz SI, Simone CB 2nd, Busch TM, Cengel KA.

Photochem Photobiol. 2018 Nov 29. doi: 10.1111/php.13067. [Epub ahead of print]

PMID:
30499112
2.

A Novel Prospective Study Assessing the Combination of Photodynamic Therapy and Proton Radiation Therapy: Safety and Outcomes When Treating Malignant Pleural Mesothelioma.

Rice SR, Li YR, Busch TM, Kim MM, McNulty S, Dimofte A, Zhu TC, Cengel KA, Simone CB 2nd.

Photochem Photobiol. 2018 Nov 28. doi: 10.1111/php.13065. [Epub ahead of print]

PMID:
30485442
3.

Luminol Chemiluminescence Reports Photodynamic Therapy-Generated Neutrophil Activity In Vivo and Serves as a Biomarker of Therapeutic Efficacy.

Davis RW 4th, Snyder E, Miller J, Carter S, Houser C, Klampatsa A, Albelda SM, Cengel KA, Busch TM.

Photochem Photobiol. 2018 Oct 25. doi: 10.1111/php.13040. [Epub ahead of print]

PMID:
30357853
4.

Adjuvant, neoadjuvant, and definitive radiation therapy for malignant pleural mesothelioma.

Cramer G, Simone CB 2nd, Busch TM, Cengel KA.

J Thorac Dis. 2018 Aug;10(Suppl 21):S2565-S2573. doi: 10.21037/jtd.2018.07.65. Review.

5.

Protoporphyrin IX (PpIX)-Coated Superparamagnetic Iron Oxide Nanoparticle (SPION) Nanoclusters for Magnetic Resonance Imaging and Photodynamic Therapy.

Yan L, Amirshaghaghi A, Huang D, Miller J, Stein JM, Busch TM, Cheng Z, Tsourkas A.

Adv Funct Mater. 2018 Apr 17;28(16). pii: 1707030. doi: 10.1002/adfm.201707030. Epub 2018 Feb 15.

PMID:
29910700
6.

A preclinical model to investigate the role of surgically-induced inflammation in tumor responses to intraoperative photodynamic therapy.

Davis RW 4th, Papasavvas E, Klampatsa A, Putt M, Montaner LJ, Culligan MJ, McNulty S, Friedberg JS, Simone CB 2nd, Singhal S, Albelda SM, Cengel KA, Busch TM.

Lasers Surg Med. 2018 Jul;50(5):440-450. doi: 10.1002/lsm.22934. Epub 2018 May 25.

PMID:
29799130
7.

Lesion oxygenation associates with clinical outcomes in premalignant and early stage head and neck tumors treated on a phase 1 trial of photodynamic therapy.

Ahn PH, Finlay JC, Gallagher-Colombo SM, Quon H, O'Malley BW Jr, Weinstein GS, Chalian A, Malloy K, Sollecito T, Greenberg M, Simone CB 2nd, McNulty S, Lin A, Zhu TC, Livolsi V, Feldman M, Mick R, Cengel KA, Busch TM.

Photodiagnosis Photodyn Ther. 2018 Mar;21:28-35. doi: 10.1016/j.pdpdt.2017.10.015. Epub 2017 Nov 4.

PMID:
29113960
8.

31 P NMR Evidence for Peroxide Intermediates in Lipid Emulsion Photooxidations: Phosphine Substituent Effects in Trapping.

Mohapatra PP, Chiemezie CO, Kligman A, Kim MM, Busch TM, Zhu TC, Greer A.

Photochem Photobiol. 2017 Nov;93(6):1430-1438. doi: 10.1111/php.12810. Epub 2017 Sep 4.

PMID:
28722754
9.

Improved Photodynamic Therapy Efficacy of Protoporphyrin IX-Loaded Polymeric Micelles Using Erlotinib Pretreatment.

Yan L, Miller J, Yuan M, Liu JF, Busch TM, Tsourkas A, Cheng Z.

Biomacromolecules. 2017 Jun 12;18(6):1836-1844. doi: 10.1021/acs.biomac.7b00274. Epub 2017 May 1.

10.

A Comparison of Dose Metrics to Predict Local Tumor Control for Photofrin-mediated Photodynamic Therapy.

Qiu H, Kim MM, Penjweini R, Finlay JC, Busch TM, Wang T, Guo W, Cengel KA, Simone CB 2nd, Glatstein E, Zhu TC.

Photochem Photobiol. 2017 Jul;93(4):1115-1122. doi: 10.1111/php.12719. Epub 2017 Feb 22.

11.

Toxicities and early outcomes in a phase 1 trial of photodynamic therapy for premalignant and early stage head and neck tumors.

Ahn PH, Quon H, O'Malley BW, Weinstein G, Chalian A, Malloy K, Atkins JH, Sollecito T, Greenberg M, McNulty S, Lin A, Zhu TC, Finlay JC, Cengel K, Livolsi V, Feldman M, Mick R, Busch TM.

Oral Oncol. 2016 Apr;55:37-42. doi: 10.1016/j.oraloncology.2016.01.013. Epub 2016 Feb 8.

12.

Fluence Rate Differences in Photodynamic Therapy Efficacy and Activation of Epidermal Growth Factor Receptor after Treatment of the Tumor-Involved Murine Thoracic Cavity.

Grossman CE, Carter SL, Czupryna J, Wang L, Putt ME, Busch TM.

Int J Mol Sci. 2016 Jan 14;17(1). pii: E101. doi: 10.3390/ijms17010101.

13.

Fluorinated Photodynamic Therapy Device Tips and their Resistance to Fouling for In Vivo Sensitizer Release.

Ghogare AA, Miller JM, Mondal B, Lyons AM, Cengel KA, Busch TM, Greer A.

Photochem Photobiol. 2016 Jan-Feb;92(1):166-72. doi: 10.1111/php.12538. Epub 2015 Nov 4.

14.

Erlotinib Pretreatment Improves Photodynamic Therapy of Non-Small Cell Lung Carcinoma Xenografts via Multiple Mechanisms.

Gallagher-Colombo SM, Miller J, Cengel KA, Putt ME, Vinogradov SA, Busch TM.

Cancer Res. 2015 Aug 1;75(15):3118-26. doi: 10.1158/0008-5472.CAN-14-3304. Epub 2015 Jun 8.

15.

Measuring the Physiologic Properties of Oral Lesions Receiving Fractionated Photodynamic Therapy.

Gallagher-Colombo SM, Quon H, Malloy KM, Ahn PH, Cengel KA, Simone CB 2nd, Chalian AA, O'Malley BW, Weinstein GS, Zhu TC, Putt ME, Finlay JC, Busch TM.

Photochem Photobiol. 2015 Sep-Oct;91(5):1210-8. doi: 10.1111/php.12475. Epub 2015 Jul 2.

16.

The PI3K/Akt Pathway Regulates Oxygen Metabolism via Pyruvate Dehydrogenase (PDH)-E1α Phosphorylation.

Cerniglia GJ, Dey S, Gallagher-Colombo SM, Daurio NA, Tuttle S, Busch TM, Lin A, Sun R, Esipova TV, Vinogradov SA, Denko N, Koumenis C, Maity A.

Mol Cancer Ther. 2015 Aug;14(8):1928-38. doi: 10.1158/1535-7163.MCT-14-0888. Epub 2015 May 20.

17.

In-vivo singlet oxygen threshold doses for PDT.

Zhu TC, Kim MM, Liang X, Finlay JC, Busch TM.

Photonics Lasers Med. 2015 Feb;4(1):59-71.

18.

Photoactive fluoropolymer surfaces that release sensitizer drug molecules.

Ghosh G, Minnis M, Ghogare AA, Abramova I, Cengel KA, Busch TM, Greer A.

J Phys Chem B. 2015 Mar 12;119(10):4155-64. doi: 10.1021/acs.jpcb.5b00808. Epub 2015 Feb 26.

19.

Parameter determination for BPD mediated vascularPDT.

Kim MM, Liu B, Miller J, Busch TM, Zhu TC.

Proc SPIE Int Soc Opt Eng. 2014 Mar 5;8931. pii: 89311D.

20.

Comparison of PDT parameters for RIF and H460 tumor models during HPPH-mediated PDT.

Liu B, Kim MM, Gallagher-Colombo SM, Busch TM, Zhu TC.

Proc SPIE Int Soc Opt Eng. 2014 Mar 5;8931. pii: 89311C.

21.

Comparison of singlet oxygen threshold dose for PDT.

Zhu TC, Liu B, Kim MM, McMillan D, Liang X, Finlay JC, Busch TM.

Proc SPIE Int Soc Opt Eng. 2014 Feb 1;8931. pii: 89310I.

22.

Determination of tissue optical properties in PDT treated Head & Neck patients.

Dimofte A, Finlay JC, Sharikova AV, Cengel KA, Ahn P, Busch TM, Zhu TC.

Proc SPIE Int Soc Opt Eng. 2014 Feb 1;8926. pii: 89262C.

23.
24.

Radiation mitigating properties of the lignan component in flaxseed.

Pietrofesa R, Turowski J, Tyagi S, Dukes F, Arguiri E, Busch TM, Gallagher-Colombo SM, Solomides CC, Cengel KA, Christofidou-Solomidou M.

BMC Cancer. 2013 Apr 4;13:179. doi: 10.1186/1471-2407-13-179.

25.

Photodynamic therapy activated signaling from epidermal growth factor receptor and STAT3: Targeting survival pathways to increase PDT efficacy in ovarian and lung cancer.

Edmonds C, Hagan S, Gallagher-Colombo SM, Busch TM, Cengel KA.

Cancer Biol Ther. 2012 Dec;13(14):1463-70. doi: 10.4161/cbt.22256. Epub 2012 Sep 17.

26.

Photodynamic therapy-induced angiogenic signaling: consequences and solutions to improve therapeutic response.

Gallagher-Colombo SM, Maas AL, Yuan M, Busch TM.

Isr J Chem. 2012 Sep 1;52(8-9):681-690.

27.

Tumor blood flow differs between mouse strains: consequences for vasoresponse to photodynamic therapy.

Mesquita RC, Han SW, Miller J, Schenkel SS, Pole A, Esipova TV, Vinogradov SA, Putt ME, Yodh AG, Busch TM.

PLoS One. 2012;7(5):e37322. doi: 10.1371/journal.pone.0037322. Epub 2012 May 18.

28.

Tumor vascular microenvironment determines responsiveness to photodynamic therapy.

Maas AL, Carter SL, Wileyto EP, Miller J, Yuan M, Yu G, Durham AC, Busch TM.

Cancer Res. 2012 Apr 15;72(8):2079-88. doi: 10.1158/0008-5472.CAN-11-3744. Epub 2012 Feb 28.

29.

Photodynamic therapy of disseminated non-small cell lung carcinoma in a murine model.

Grossman CE, Pickup S, Durham A, Wileyto EP, Putt ME, Busch TM.

Lasers Surg Med. 2011 Sep;43(7):663-75. doi: 10.1002/lsm.21102.

30.

Two new "protected" oxyphors for biological oximetry: properties and application in tumor imaging.

Esipova TV, Karagodov A, Miller J, Wilson DF, Busch TM, Vinogradov SA.

Anal Chem. 2011 Nov 15;83(22):8756-65. doi: 10.1021/ac2022234. Epub 2011 Oct 17.

31.

Evaluation of bacteriochlorophyll-reconstituted low-density lipoprotein nanoparticles for photodynamic therapy efficacy in vivo.

Marotta DE, Cao W, Wileyto EP, Li H, Corbin I, Rickter E, Glickson JD, Chance B, Zheng G, Busch TM.

Nanomedicine (Lond). 2011 Apr;6(3):475-87. doi: 10.2217/nnm.11.8.

32.

Photodynamic therapy in the management of pre-malignant head and neck mucosal dysplasia and microinvasive carcinoma.

Quon H, Grossman CE, Finlay JC, Zhu TC, Clemmens CS, Malloy KM, Busch TM.

Photodiagnosis Photodyn Ther. 2011 Jun;8(2):75-85. doi: 10.1016/j.pdpdt.2011.01.001. Review.

33.

Evaluation of phototoxicity of dendritic porphyrin-based phosphorescent oxygen probes: an in vitro study.

Ceroni P, Lebedev AY, Marchi E, Yuan M, Esipova TV, Bergamini G, Wilson DF, Busch TM, Vinogradov SA.

Photochem Photobiol Sci. 2011 Jun;10(6):1056-65. doi: 10.1039/c0pp00356e. Epub 2011 Mar 15.

34.

Interference with the Jaffé method for creatinine following 5-aminolevulinic acid administration.

Quon H, Grossman CE, King RL, Putt M, Donaldson K, Kricka L, Finlay J, Zhu T, Dimofte A, Malloy K, Cengel KA, Busch TM.

Photodiagnosis Photodyn Ther. 2010 Dec;7(4):268-74. doi: 10.1016/j.pdpdt.2010.07.008. Epub 2010 Aug 30.

35.

Targeted laryngeal photodynamic therapy with a balloon diffusing light source.

Grossman C, Zhu T, Finlay J, Dimofte A, Malloy K, O'Malley B Jr, Weinstein G, Busch TM, Quon H.

Photodiagnosis Photodyn Ther. 2010 Sep;7(3):158-61. doi: 10.1016/j.pdpdt.2010.06.001. Epub 2010 Aug 3.

36.

Increasing damage to tumor blood vessels during motexafin lutetium-PDT through use of low fluence rate.

Busch TM, Wang HW, Wileyto EP, Yu G, Bunte RM.

Radiat Res. 2010 Sep;174(3):331-40. doi: 10.1667/RR2075.1.

37.

Hypoxia and perfusion labeling during photodynamic therapy.

Busch TM.

Methods Mol Biol. 2010;635:107-20. doi: 10.1007/978-1-60761-697-9_8.

PMID:
20552343
38.

Explicit dosimetry for photodynamic therapy: macroscopic singlet oxygen modeling.

Wang KK, Finlay JC, Busch TM, Hahn SM, Zhu TC.

J Biophotonics. 2010 Jun;3(5-6):304-18. doi: 10.1002/jbio.200900101.

39.

Fluence rate-dependent intratumor heterogeneity in physiologic and cytotoxic responses to Photofrin photodynamic therapy.

Busch TM, Xing X, Yu G, Yodh A, Wileyto EP, Wang HW, Durduran T, Zhu TC, Wang KK.

Photochem Photobiol Sci. 2009 Dec;8(12):1683-93. doi: 10.1039/b9pp00004f. Epub 2009 Oct 15.

40.
41.

Motexafin lutetium-photodynamic therapy of prostate cancer: short- and long-term effects on prostate-specific antigen.

Patel H, Mick R, Finlay J, Zhu TC, Rickter E, Cengel KA, Malkowicz SB, Hahn SM, Busch TM.

Clin Cancer Res. 2008 Aug 1;14(15):4869-76. doi: 10.1158/1078-0432.CCR-08-0317.

42.

Effect of photosensitizer dose on fluence rate responses to photodynamic therapy.

Wang HW, Rickter E, Yuan M, Wileyto EP, Glatstein E, Yodh A, Busch TM.

Photochem Photobiol. 2007 Sep-Oct;83(5):1040-8.

PMID:
17880498
43.

Quantitative comparison of tissue oxygen and motexafin lutetium uptake by ex vivo and noninvasive in vivo techniques in patients with intraperitoneal carcinomatosis.

Wang HW, Finlay JC, Lee K, Zhu TC, Putt ME, Glatstein E, Koch CJ, Evans SM, Hahn SM, Busch TM, Yodh AG.

J Biomed Opt. 2007 May-Jun;12(3):034023.

PMID:
17614731
44.

Photofrin uptake in the tumor and normal tissues of patients receiving intraperitoneal photodynamic therapy.

Hahn SM, Putt ME, Metz J, Shin DB, Rickter E, Menon C, Smith D, Glatstein E, Fraker DL, Busch TM.

Clin Cancer Res. 2006 Sep 15;12(18):5464-70.

45.

Interstitial fluorescence spectroscopy in the human prostate during motexafin lutetium-mediated photodynamic therapy.

Finlay JC, Zhu TC, Dimofte A, Stripp D, Malkowicz SB, Busch TM, Hahn SM.

Photochem Photobiol. 2006 Sep-Oct;82(5):1270-8.

46.

Preliminary results of interstitial motexafin lutetium-mediated PDT for prostate cancer.

Du KL, Mick R, Busch TM, Zhu TC, Finlay JC, Yu G, Yodh AG, Malkowicz SB, Smith D, Whittington R, Stripp D, Hahn SM.

Lasers Surg Med. 2006 Jun;38(5):427-34.

PMID:
16788929
47.

Local physiological changes during photodynamic therapy.

Busch TM.

Lasers Surg Med. 2006 Jun;38(5):494-9. Review.

PMID:
16788920
48.

Real-time in situ monitoring of human prostate photodynamic therapy with diffuse light.

Yu G, Durduran T, Zhou C, Zhu TC, Finlay JC, Busch TM, Malkowicz SB, Hahn SM, Yodh AG.

Photochem Photobiol. 2006 Sep-Oct;82(5):1279-84.

PMID:
16696593
49.

Photodynamic therapy with motexafin lutetium for rectal cancer: a preclinical model in the dog.

Ross HM, Smelstoys JA, Davis GJ, Kapatkin AS, Del Piero F, Reineke E, Wang H, Zhu TC, Busch TM, Yodh AG, Hahn SM.

J Surg Res. 2006 Oct;135(2):323-30. Epub 2006 May 2.

PMID:
16650871
50.

A phase II trial of intraperitoneal photodynamic therapy for patients with peritoneal carcinomatosis and sarcomatosis.

Hahn SM, Fraker DL, Mick R, Metz J, Busch TM, Smith D, Zhu T, Rodriguez C, Dimofte A, Spitz F, Putt M, Rubin SC, Menon C, Wang HW, Shin D, Yodh A, Glatstein E.

Clin Cancer Res. 2006 Apr 15;12(8):2517-25.

Supplemental Content

Loading ...
Support Center